Sun.Jan 22, 2023

article thumbnail

Nvidia’s AI Tech Designs Proteins Never Seen in Nature, Pointing Way to New Therapies

MedCity News

A collaboration between Nvidia and startup Evozyne was able to produce novel versions of a human protein never before seen in nature but with enhanced function and the same safety as native protein. The research lays the groundwork for potential new therapies for a rare inherited disorder.

Safety 143
article thumbnail

FDA accepts Lilly-Boehringer Ingelheim’ sNDA for Jardiance

Pharmaceutical Technology

Eli Lilly and Company and Boehringer Ingelheim have announced that the US Food and Drug Administration (FDA) accepted a supplemental New Drug Application (sNDA) for Jardiance (empagliflozin) tablets for chronic kidney disease (CKD) in adult patients. Jardiance is currently being evaluated as a potential therapy for reducing kidney disease progression and cardiovascular death risk in CKD adult patients.

Insiders

Sign Up for our Newsletter

This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

Trending Sources

article thumbnail

Behavioral Health Company Launches to Help Health Plan Members Navigate Care

MedCity News

The new company is called Lucet and was created out of the 2022 merger between New Directions Behavioral Health and Tridiuum. Lucet unveiled its solution called Navigate & Connect, which helps connect health plan members to behavioral health care.

117
117
article thumbnail

How can pharma teams optimise their HCP portals to strengthen HCP relationships and impact patient outcomes?

pharmaphorum

In recent years, pharma companies have invested heavily in their healthcare provider (HCP) portals, along with other digital solutions, to account for the reduction in face-to-face time between reps and HCPs during and post-pandemic. While the concept of HCP portals is a good one, the perception and impact has sometimes been underwhelming. Many organisations report low engagement amongst HCPs, and HCPs themselves talk of frustrations when it comes to utilising pharma-sponsored portals.

Pharma 98
article thumbnail

Roles and Responsibilities of Specialized Clinical Supply Experts

When selecting a clinical supply provider, consideration often focuses upon the manufacturing, packaging, storage and distribution capabilities available that will, at face-value, be sufficient to meet the needs of the sponsor and their trial. However, there are human-based and knowledge-driven factors that are often overlooked that go beyond these basic physical capabilities and are integral to the development and delivery of high performing clinical supply chains.

article thumbnail

Report: Majority of Top Health Systems are Spending More on Interoperability This Year

MedCity News

More than half of technology leaders at the country’s top 50 health systems by net patient revenue said they’re investing more money into interoperability initiatives in 2023 than they did last year, according to a new report. Participating in health information exchanges is a key way that health systems strengthen their interoperability strategy.

Patients 107
article thumbnail

Can the FDA keep the momentum going for rare disease drug approvals?

Pharmaceutical Technology

In 2022, the FDA approved only 37 new medicines, an underwhelming number compared to 98 in 2018. However, while only around 34% of the approvals in 2018 were for orphan drugs, 54% new approvals in 2022 were for drugs to treat rare diseases. Major pharmaceutical acquisitions have taken place in recent months in the rare disease space, as the number of orphan drug approvals continues to grow.

FDA 126